Previous investigations showed that imatinib is the substrate of MDR1 and considered drug efflux mediated by MDR1 as a causal role for imatinib drug resistance in CML [14, 15]. Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.